Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and Zoledronic Acid
2024-519705-36-00Phase 4Completed
- Sponsor
- University of Edinburgh
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 4 trial of teriparatide and romosozumab in osteogenesis imperfecta (OI), sponsored by University of Edinburgh. Started Dec 2024; status: completed.
02
Drugs
teriparatideromosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2024-519705-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519705-36-00.